Biologic compounds directed against death receptor 5
US9120855B2 · kind B2 · utility
6Cited by
4References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 9, 2011 |
| Grant date | Sep 1, 2015 |
| Priority date | — |
| Expiry date | Aug 19, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to amino acid sequences that are directed against TRAIL cell surface receptor 2 (herein also “DR5”), as well as to compounds or constructs thereof, and in particular proteins and polypeptides and nucleotides that encode them (referred to herein in their entirety as “NB agents”) and fragments thereof, and pharmaceutically effective variants thereof, and their use in the diagnosis and treatment of DR5 associated diseases and disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.